Pier Capital, LLC Allogene Therapeutics, Inc. Transaction History

Pier Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$5.62 - $11.11 $4,203 - $8,310	-748 Reduced 0.28%	262,832 $1.65 Million
Q3 2022 Nov 15, 2022	SELL	$10.32 - $17.28 $4.92 Million - $8.24 Million	-476,976 Reduced 64.41%	263,580 $2.85 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $41,446 - $75,067	-6,113 Reduced 0.82%	740,556 $8.44 Million
Q1 2022 May 10, 2022	BUY	$7.65 - $15.29 $3.46 Million - $6.91 Million	451,701 Added 153.14%	746,669 $6.8 Million
Q4 2021 Feb 10, 2022	SELL	$13.13 - $24.52 $2.04 Million - $3.81 Million	-155,214 Reduced 34.48%	294,968 $4.4 Million
Q3 2021 Nov 10, 2021	BUY	$21.01 - $27.64 $3.6 Million - $4.74 Million	171,354 Added 61.46%	450,182 $11.6 Million
Q2 2021 Aug 12, 2021	BUY	$23.49 - $35.8 $121,725 - $185,515	5,182 Added 1.89%	278,828 $7.27 Million
Q1 2021 May 13, 2021	BUY	$25.79 - $39.02 $3.14 Million - $4.74 Million	121,575 Added 79.95%	273,646 $9.66 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $96,997 - $166,978	3,843 Added 2.59%	152,071 $3.84 Million
Q3 2020 Nov 13, 2020	BUY	$32.38 - $44.96 $4.8 Million - $6.66 Million	148,228 New	148,228 $5.59 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $262M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.